Search research articles
Contact Us
Filters
Showing results (121-130 of 137) with videos related to
Page
of 14
Sort By:
British Journal of Cancer
|
March 1, 1996
Recombinant human interleukin 6 in metastatic renal cell cancer: a phase II trial
J M Stouthard, H Goey, E G de Vries, et al.
Journal of the National Cancer Institute
|
May 26, 1999
Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party
L Collette, R J Sylvester, S P Stenning, et al.
Clinical and Experimental Immunology
|
December 22, 1999
Cytokines and soluble cytokine receptor induction after IL-12 administration in cancer patients
N Haicheur, B Escudier, T Dorval, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 17, 2001
Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council
R de Wit, J T Roberts, P M Wilkinson, et al.
British Journal of Cancer
|
June 1, 1995
Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group
R de Wit, G Stoter, D T Sleijfer, et al.
British Journal of Haematology
|
October 1, 1991
Clinical experience with the combined use of recombinant interleukin-2 (IL2) and interferon alfa-2a (IFN alpha) in metastatic melanoma
W H Kruit, S H Goey, J R Monson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 22, 2000
A multi-center prospective phase II study of high-dose chemotherapy in germ-cell cancer patients relapsing from complete remission
S Rodenhuis, R de Wit, P H de Mulder, et al.
Cancer Immunology, Immunotherapy : CII
|
July 1, 1995
Therapy of bovine ocular squamous-cell carcinoma with local doses of interleukin-2: 67% complete regressions after 20 months of follow-up
W Den Otter, F W Hill, W R Klein, et al.
Journal of the National Cancer Institute
|
June 16, 1993
Cytokine release in an ovarian carcinoma patient following intravenous administration of bispecific antibody OC/TR F(ab')2
J G Tibben, O C Boerman, R A Claessens, et al.
British Journal of Cancer
|
November 21, 1998
Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance
R de Wit, L Collette, R Sylvester, et al.
Page
of 14
Search research articles
Search
Showing results (121-130 of 137) with videos related to
Sort By:
Page
of 14
British Journal of Cancer
|
March 1, 1996
Recombinant human interleukin 6 in metastatic renal cell cancer: a phase II trial
J M Stouthard, H Goey, E G de Vries, et al.
Journal of the National Cancer Institute
|
May 26, 1999
Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party
L Collette, R J Sylvester, S P Stenning, et al.
Clinical and Experimental Immunology
|
December 22, 1999
Cytokines and soluble cytokine receptor induction after IL-12 administration in cancer patients
N Haicheur, B Escudier, T Dorval, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 17, 2001
Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council
R de Wit, J T Roberts, P M Wilkinson, et al.
British Journal of Cancer
|
June 1, 1995
Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group
R de Wit, G Stoter, D T Sleijfer, et al.
British Journal of Haematology
|
October 1, 1991
Clinical experience with the combined use of recombinant interleukin-2 (IL2) and interferon alfa-2a (IFN alpha) in metastatic melanoma
W H Kruit, S H Goey, J R Monson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 22, 2000
A multi-center prospective phase II study of high-dose chemotherapy in germ-cell cancer patients relapsing from complete remission
S Rodenhuis, R de Wit, P H de Mulder, et al.
Cancer Immunology, Immunotherapy : CII
|
July 1, 1995
Therapy of bovine ocular squamous-cell carcinoma with local doses of interleukin-2: 67% complete regressions after 20 months of follow-up
W Den Otter, F W Hill, W R Klein, et al.
Journal of the National Cancer Institute
|
June 16, 1993
Cytokine release in an ovarian carcinoma patient following intravenous administration of bispecific antibody OC/TR F(ab')2
J G Tibben, O C Boerman, R A Claessens, et al.
British Journal of Cancer
|
November 21, 1998
Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance
R de Wit, L Collette, R Sylvester, et al.
Page
of 14